Stephens Rates Bio-Techne (TECH) hold, $73 Price Target

Stephens downgraded TECH to a hold with a $73 price target, a 3.25% upside from the current price.

By EarningsIQ Research Desk · Published Jun 26, 2026, 12:01 PM EDT · Updated Jun 27, 2026, 2:01 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Stephens rated Bio-Techne Corporation ($TECH) "hold" with a $73 price target on June 26, 2026.

Since the rating, $TECH is down 0.1% after 1 week, up 0.9% after 1 month and up 2.3% to date (from the $70.92 close on Jun 26, 2026).

TECH Bio-Techne Corporation

$72.57 +22.19% year to date

Daily close · Oct 16, 2026

Key Points

Stephens downgraded TECH to a hold rating on June 26, 2026, setting a price target at $73 as the stock traded near $70.70.
Stephens's $73 price target implies 3.25% upside from Bio-Techne Corporation's ($TECH) current $70.70 share price.
Shares of TECH saw institutional activity with BlackRock and Morgan Stanley increasing their holdings, while FMR LLC significantly boosted its position.
Insider activity included sales and buys by executives, with Amy Herr purchasing and selling shares on May 8, 2026.

Get $TECH trade alerts by text

We text you when insiders, Congress or big funds trade $TECH. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Bio-Techne Corporation alert may contain errors. Disclosures

On June 26, 2026, Stephens lowered its rating on TECH to a hold, setting a price target of $73. This downgrade came as TECH's shares were trading around $70.70 on Friday.

Analyst rating track record

Stephens & Co. vs. the S&P 500

YTD return +15.76% hypothetical

All-time return -7.08% S&P 500 +26.92%

vs. S&P 500 -34% behind the index

Hypothetical returns from Stephens & Co.'s disclosed trades, not real profit or advice. How we model this.

Other Institutional Activity in TECH

Institutional investors have been actively trading TECH. BlackRock, Inc. increased its holdings by 135,388 shares, bringing its total to 12,264,513 shares valued at approximately $640.9 million, marking a 1.1% increase. Morgan Stanley also added to its position, with an increase of 187,459 shares, ending with 8,532,873 shares worth about $445.9 million, reflecting a 2.2% rise. FMR LLC made a significant move by increasing its stake by 6,884,967 shares, resulting in a total of 7,899,928 shares valued at $412.9 million, a substantial 678.3% increase. Meanwhile, Vanguard Capital Management LLC and Vanguard Portfolio Management LLC both opened new positions with 10,179,709 and 6,480,337 shares respectively.

Insider Buying and Selling at Bio-Techne Corporation

Insider activity at TECH has been notable. On June 2, 2026, Steven Crouse, President of Diagnostics & Spatial Biology, sold 600 shares and also bought 600 shares on the same day. On May 8, 2026, Amy Herr purchased 6,636 shares at $47.60 and later sold the same amount at prices of $47.60 and $48.28.

Analysts Set New Price Targets

On June 26, 2026, Stephens & Co. downgraded TECH to a hold rating, setting a price target of $73. On the same day, Baird maintained its hold rating with the same target price. Earlier, on June 11, 2026, Piper Sandler initiated coverage with a hold rating and a $65 target. RBC Capital reinstated a buy rating with a $62 target on May 15, 2026. Citigroup and Wells Fargo both maintained buy ratings with target prices of $70 and $62, respectively, in early May.

Bottom Line

Stephens' decision to lower its rating on TECH to hold with a $73 target highlights a cautious stance on the stock's outlook. Institutional investors have shown varied interest, with some increasing their stakes significantly, while others are just initiating positions. Insider transactions reveal ongoing activity among executives, and analysts continue to provide mixed ratings, reflecting uncertainty in the market. As always, these ratings are backward-looking and may not reflect the current market sentiment.

12-month forecast